Publications - NEO 212
NEO-212 Shows Promise In Treating Acute Myeloid Leukemia
Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia. Authors: Axel H. Schönthal 1, Steve Swenson2, Radu O. Minea2, Hye Na Kim3, Heeyeon Cho2, Nazleen...
Understanding The Pharmacokinetic Properties Of NEO 212
Pharmacokinetic Properties of the Temozolomide Perillyl Alcohol Conjugate (NEO212) in Mice. Authors: Thomas C Chen, M.D., PhD 1,4, Hee-Yeon Cho1, Steve Swenson1, Thu Zan Thein1, Weijun Wang1, Neloni R. Wijeratne2, Nagore I. Marín-Ramos1, Jonathan E. Katz2, Florence M....
NEO 212 Enhances Temozolomide’s Ability To Increase Radiosensitivity And Cytotoxicity In Glioblastoma Tumors
Developing A Clinically Relevant Radiosensitizer For Temozolomide-Resistant Gliomas. Authors: Radu O. Minea1, Tuan Cao Duc2, Stephen D. Swenson1, Hee-Yeon Cho1, Mickey Huang3, Hannah Hartman4, Florence M. Hofman5, Axel H. Schonthal4and Thomas C. Chen1,5 A new study...
Further NEO 212 Studies Shows Ability To Slow GBM Cell Invasion at Sub-Cytotoxic Dose
NEO 212 Sub-Cytotoxic Doses Capable of Inhibiting Glioma Stem Cell Invasion. Authors: Thomas C. Chen1, Nagore I. Marín-Ramos1, and Florance M. Hofman2 Glioblastoma multiforme (GBM) is a malignant brain tumor characterized by its extensive vascularity, aggressiveness,...
NEO 212 Inhibits Migration and Invasion of Glioma Stem Cells
A Novel Temozolomide–Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells In Vitro and Intracranial Triple-Negative Tumor Growth In Vivo. Authors: Thomas C. Chen1,2, Hee-Yeon Cho1, Weijun Wang1, Manasai Barath3, Natasha Sharma4, Florance...
NEO 212 Shown To Downregulate Production of MGMT For Treatment Of Non-Small Cell Lung Cancer
Temozolomide–perillyl alcohol conjugate downregulates O6- methylguanin DNA methltransferase via inducing ubiquitination-dependent proteolysis in non-small cell lung cancer (NSCLC). Authors: Xingguo Song1, Li Xie1,2, Minghui Chang2,3, Xinran Geng4, Xingwu Wang1, Thomas...